|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.30 HKD | -0.05% |
|
-4.14% | -5.81% |
| 01-14 | Shares of Trip.com tumble in Hong Kong after antitrust probe | RE |
| 12-30 | Novo and Lilly cut prices of weight-loss drugs in China | RE |
Company Valuation: Meituan
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,459,604 | 1,126,727 | 957,019 | 464,216 | 861,878 | 530,685 | 530,685 | - |
| Change | - | -22.81% | -15.06% | -51.49% | 85.66% | -38.43% | 0% | - |
| Enterprise Value (EV) 1 | 1,422,568 | 1,068,850 | 883,100 | 354,226 | 729,838 | 421,514 | 412,983 | 391,197 |
| Change | - | -24.86% | -17.38% | -59.89% | 106.04% | -42.25% | -2.02% | -5.28% |
| P/E ratio | 318x | -47.1x | -142x | 35.2x | 25.2x | -23x | 23.6x | 15.1x |
| PBR | 14.8x | 8.83x | 7.43x | 3.05x | 5.06x | 3.44x | 3.07x | 2.54x |
| PEG | - | 0x | 2x | -0x | 0x | 0x | -0x | 0.3x |
| Capitalization / Revenue | 12.7x | 6.29x | 4.35x | 1.68x | 2.55x | 1.45x | 1.27x | 1.11x |
| EV / Revenue | 12.4x | 5.97x | 4.01x | 1.28x | 2.16x | 1.15x | 0.99x | 0.82x |
| EV / EBITDA | 300x | -110x | 90.8x | 14.8x | 14.9x | -35.6x | 14.6x | 8.01x |
| EV / EBIT | 329x | -46.2x | -152x | 26.4x | 17.9x | -18.7x | 25.2x | 9.78x |
| EV / FCF | -518x | -82.1x | 155x | 10.5x | 15.8x | -26.6x | 19.3x | 11.9x |
| FCF Yield | -0.19% | -1.22% | 0.64% | 9.5% | 6.32% | -3.76% | 5.18% | 8.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.78 | -3.9 | -1.09 | 2.11 | 5.66 | -3.782 | 3.681 | 5.736 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 114,795 | 179,128 | 219,955 | 276,745 | 337,592 | 366,893 | 416,755 | 478,502 |
| EBITDA 1 | 4,738 | -9,694 | 9,725 | 23,878 | 49,119 | -11,847 | 28,279 | 48,810 |
| EBIT 1 | 4,330 | -23,127 | -5,820 | 13,415 | 40,869 | -22,560 | 16,381 | 40,019 |
| Net income 1 | 4,708 | -23,538 | -6,686 | 13,856 | 35,807 | -23,624 | 19,392 | 34,335 |
| Net Debt 1 | -37,036 | -57,876 | -73,919 | -109,991 | -132,040 | -109,171 | -117,702 | -139,488 |
| Reference price 2 | 248.06 | 183.63 | 154.53 | 74.34 | 142.55 | 86.88 | 86.88 | 86.88 |
| Nbr of stocks (in thousands) | 5,883,965 | 6,135,944 | 6,192,973 | 6,244,376 | 6,046,056 | 6,108,075 | 6,108,075 | - |
| Announcement Date | 3/26/21 | 3/25/22 | 3/24/23 | 3/22/24 | 3/21/25 | - | - | - |
1CNY in Million2CNY
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -22.97x | 1.15x | -35.58x | -.--% | 76.25B | ||
| 23.64x | 2.25x | 16.11x | 0.65% | 363B | ||
| 178.34x | 15.84x | 93.34x | -.--% | 188B | ||
| 10.25x | 1.58x | 6.62x | -.--% | 148B | ||
| 50.92x | 3.45x | 24.62x | -.--% | 103B | ||
| 21.8x | 4.06x | 13.11x | 1.27% | 41B | ||
| 24.56x | 7.08x | 16.75x | - | 39.41B | ||
| 8.68x | 0.31x | 3.38x | 2.8% | 8.47B | ||
| 103.46x | 5.78x | 28.37x | -.--% | 6.11B | ||
| 20.08x | 6.24x | 10.93x | 2.99% | 5.15B | ||
| Average | 41.88x | 4.77x | 17.77x | 0.86% | 97.9B | |
| Weighted average by Cap. | 50.89x | 5.10x | 26.22x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 3690 Stock
- Valuation Meituan
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















